Dianthus Therapeutics, Inc. (DNTH)

Market Cap	4.24B +209.3%
Revenue (ttm)	1.90M -60.8%
Net Income	-192.25M
EPS	-4.11
Shares Out	55.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	287,344
Open	77.17
Previous Close	77.58
Day's Range	75.63 - 78.78
52-Week Range	32.22 - 117.88
Beta	0.18
Analysts	Strong Buy
Price Target	140.80 (+85.56%)
Est. Earnings	Nov 4, 2026

About DNTH

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell functio...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 92
• Stock Exchange: Nasdaq
• Ticker Symbol: DNTH
• Website: https://dianthustx.com

Financial Performance

In 2025, Dianthus Therapeutics's revenue was $2.04 million, a decrease of -67.35% compared to the previous year's $6.24 million. Losses were -$162.34 million, 91.1% more than in 2024.

Analyst Summary

According to 17 analysts, the average rating for DNTH stock is "Strong Buy." The 12-month stock price target is $140.8, which is an increase of 85.56% from the latest price.

Price Target

$140.8

(85.56% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 14, 2026

Data Sources Report a data error